


RealRate

PHARMACEUTICAL 2018

Bioverativ Inc. Rank 18 of 349





PHARMACEUTICAL 2018



Bioverativ Inc. Rank 18 of 349

The relative strengths and weaknesses of Bioverativ Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Bioverativ Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 486% points. The greatest weakness of Bioverativ Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 56% points.

The company's Economic Capital Ratio, given in the ranking table, is 208%, being 485% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	778,300
Cost of Goods Sold	0
Intangible Assets	806,600
Liabilities, Current	390,100
Liabilities, Non-Current	92,500
Other Assets	9,400
Other Compr. Net Income	-1,800
Other Expenses	375,900
Other Liabilities	238,100
Other Net Income	4,700
Property and Equipment	24,000
Research and Development	224,600
Revenues	1,168,500
Selling, General and Administrative Expense	217,100

Output Variable	Value in 1000 USD
Assets	1,618,300
Liabilities	720,700
Expenses	817,600
Stockholders Equity	897,600
Net Income	355,600
Comprehensive Net Income	354,700
Economic Capital Ratio	208%